

May 30, 2024

BSE Limited	National Stock Exchange of India Ltd.			
Corporate Relationship Department	Exchange Plaza,			
P.J. Towers,	Bandra-Kurla Complex,			
Dalal Street, Fort,	Bandra (East)			
Mumbai - 400 001	Mumbai - 400 051			
Scrip Code : 506109	Symbol : GENESYS			

Dear Sirs,

Subject: Statement of Deviation or Variation or Utilization of funds raised under Preferential Issue - Regulation 32(1) of SEBI (LODR) Regulations, 2015 for the quarter ended March 31, 2024


In compliance with the Regulation 32(1) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 please find attached the Statement of Deviation or Variation or Utilization of funds raised through Preferential Issue by the Company for the quarter ended March 31, 2024 as reviewed by the Audit Committee.

You are requested to take the above on your records.

Thanking You,

Yours Faithfully, for **Genesys International Corporation Limited**

Vineet Chopra Vice President - Legal & Company Secretary




Regd. Office: 73-A, SDF-III, SEEPZ, Andheri (E), Mumbai-400 096, India Tel.: +91-22-2829 0303; +91-22-4488 4488; Fax: +91-22-2829 0603 Website: www.igenesys.com; E-mail:investors@igenesys.com



	ligations & Disclosure Requirements) Regulations, TD/CMD/162/2019 dated December 24, 2019					
N. Col. III al III al						
Name of the Listed Entity	Genesys International Corporation Limited					
Mode of Fund Raising	Public Issues / Rights Issues / Preferential Issues/ QIP / Others					
Date of Raising Funds	January 12, 2024					
Amount Raised	Rs. 56,24,97,637.50					
Report filed for Quarter ended	March 31, 2024					
Monitoring Agency, if applicable	Not Applicable					
Is there a Deviation / Variation in use of funds raised	No					
If yes, whether the same is pursuant to change in terms of a contract or objects,	Not Applicable					
which was approved by the shareholders						
Explanation for the Deviation / Variation	Not Applicable					
Comments of the Audit Committee after review	None					
Comments of the auditors, if any	Not applicable					

Regd. Office: 73-A, SDF-III, SEEPZ, Andheri (E), Mumbai-400 096, India Tel.: +91-22-2829 0303; +91-22-4488 4488; Fax: +91-22-2829 0603 Website: www.igenesys.com; E-mail:investors@igenesys.com





Obje	Objects for which funds have been raised and where there has been a deviation, in the following table									
Sr. no.	Original Object	Modified Object, if any	Original Allocation	Modified allocation, if any	Funds Utilised	Amount of Deviation/ Variation for the quarter according to applicable object	Remarks if any			
a)	Combination of part funding of the capital expenditure, support growth plans of the Company, working capital requirements, repayment of loans, investments and general corporate purposes or any combination thereof to pursue the business objects of the Company	Not Applicable	Rs. 56,24,97,6 37.50	Nil	Rs. 12,49,97, 638	Nil	Kindly refer Note			

Note: 1. The members of the Company on July 09, 2022 had approved issue of 13,04,345 Warrant convertible into equity shares at price of Rs.460/- to Malabar India Fund Limited.

The Company received Rs.44,99,99,025 i.e balance 75% of the issue price on January 12, 2024 for allotment of equity shares pursuant to exercising of warrants into equity shares. The Company on 12th January, 2024 allotted 13,04,345 equity shares to Malabar India Fund Limited.

2. The members of the Company on 9th July, 2022 had approved issue of 3,19,145 Warrant convertible into equity shares at price of Rs.470/- to Sundar Iyer.

The Company received Rs.11,24,98,612.50 i.e balance 75% of the issue price on 11th January, 2024 for allotment of equity shares pursuant to exercising of warrants into equity shares. The Company on 12th January, 2024 allotted 3,19,145 equity shares to Sundar Iyer.

Regd. Office: 73-A, SDF-III, SEEPZ, Andheri (E), Mumbai-400 096, India Tel.: +91-22-2829 0303; +91-22-4488 4488; Fax: +91-22-2829 0603 Website: www.igenesys.com; E-mail:investors@igenesys.com





Deviation or variation could mean:

- (a) Deviation in the objects or purposes for which the fund have been raised or
- (b) Deviation in the amount of funds actually utilized as against what was originally disclosed or
- (c) Change in terms of a contract referred to in the fund raising document i.e. prospectus, letter of offer, etc

For Genesys International Corporation Limited

Vineet Chopra Vice President - Legal & Company Secretary

Date: 30.05.2024 Place: Mumbai



Regd. Office: 73-A, SDF-III, SEEPZ, Andheri (E), Mumbai-400 096, India Tel.: +91-22-2829 0303; +91-22-4488 4488; Fax: +91-22-2829 0603 Website: www.igenesys.com; E-mail:investors@igenesys.com

